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Abstract 
Deleterious mitochondrial mutations accumulate during normal human aging in postmitotic tissues. How these mutations affect aging 
cells is currently unknown. This issue has been addressed in two ways. The first is to determine the likeliest effect of random mutations in 
the mitochondrial genome, and of the 4977 bp deletion and MELAS point mutation that rise in frequency with age. The results indicate 
that Complex ! is statistically much more likely to be affected than any other product of the mitochondrial genome. We have also 
attempted to model Complex I deficiency in animals with the drug MPTP, a specific inhibitor of Complex I. We find that MPTP causes 
massive damage in brains of mice with a genetic deficiency in the mitochondrial superoxide dismutase, MnSOD, but less in mice that 
overexpress the enzyme. We conclude from these data that MPTP-induced cell death must be mediated through an increase in the 
steady-state concentration of superoxide anion in mitochondria. Since the likeliest target of mitochondrial mutation is Complex I, 
deficiency of which causes MnSOD-inhibitable thality, we propose that rising mtDNA mutations with age will cause an increase in 
superoxide-mediated c ll death. Such a mechanism for age-related cell death has the potential to explain several age-related phenotypes. 
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I. Introduction 
Several degenerative diseases occur in the aged, and the 
molecular basis of most of these are still unexplained [1]. 
Many of the phenotypes of age-related egenerative dis- 
ease are associated with deficiencies of function in postmi- 
totic cells, including age-related hearing loss, progressive 
muscle weakness, ataxia, dementia, and cardiomyopathy. It 
is difficult to explain such deficiencies in the context of 
one popular model of aging called replicative senescence, 
in which cells reach a replicative barrier at a particular 
number of cell divisions, because the nuclear genomes of 
the cells which fail in these age-related egenerative dis- 
eases have usually not replicated since parturition. 
By contrast, a mitochondrial model for aging may 
explain how aging phenotypes arise in postmitotic tissues 
[2-7]. Unlike the nucleus, the mitochondrial genome con- 
tinues to replicate in postmitotic cells about once per 
month [8], and so the average mtDNA in a neuron of an 
84-year-old may have undergone approx. 1000 replica- 
tions. In addition to vulnerability to mutation that is the 
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result of replication, mtDNA is located in the mitochon- 
drial matrix, the site of generation of reactive and muta- 
genic oxygen species [9,10]. 
Such considerations prompted the inspection of mtDNA 
of normally aging humans for particular deleterious muta- 
tions which had previously only been described in persons 
with mitochondrial genetic disease [3-7]. It was shown 
that mitochondria exhibit more than 100-fold increase in 
mutation frequency with age in heart and brain [3]. This 
level of increase in a particular biomarker of aging was 
unprecedented in aging research. Mitochondrial DNA mu- 
tations occur with a strikingly characteristic tissue speci- 
ficity, in postmitotic ells of aging humans [7]. Cells of the 
substantia nigra contain the highest level of mtDNA muta- 
tion in the brain [11-13], and these cells die earlier in 
Parkinsonian individuals than in normally aging humans. 
Death of nigral cells can be specifically induced by the 
mitochondrial Complex I poison MPTP [14]. 
The aim of work presented here is to determine what 
effect a rise in mitochondrial mutations with age may have 
on cells, by calculating which mitochondrially-encoded 
enzymes are most likely to be affected by random muta- 
tions, and by two age-associated mutations which have 
been reported to rise in frequency in aging human tissue. 
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Preliminary attempts to model Complex I deficiency in 
animals are also described. A model for how mitochondrial 
superoxide may mediate death of Complex I-deficient cells 
is presented, as is a model for how early cell death 
mediated by mitochondrial superoxide could induce age- 
related egenerative disease. 
2. Materials and methods 
2.1. Calculation of mtDNA bases encoding mitochondrial 
proteins and UUR and CUN codon usage, mutant MnSOD 
mice and SOD activity measurements 
Calculations were based on the Cambridge mtDNA 
sequence [15]. Spectrophotometric and gel measurements 
of MnSOD activity are as described [16]. All mice used 
were from the Jackson Laboratory. 
3. Results 
3.1. Random mutations in coding mtDNA are most likely to 
occur in Complex I 
The mitochondrial genome encodes 13 proteins, ND 
1-6, ND4L, COI, COII and COIII, ATPase 6 and 8, and 
cytochrome b [15]. Seven of the 13 proteins are subunits 
of Complex I. The number of mitochondrial base pairs 
directly encoding protein (counting the overlap of ATPase 
6 and 8 messages once) is 11320. Of those 11320 bases, 
bases directly encoding Complex I subunits make up 6338 
or 56%. Therefore a random mutation in any part of the 
mitochondrial genome encoding protein is more likely to 
occur in Complex I than any other mitochondrially en- 
coded protein (Table 1). Mutations in ribosomal RNA and 
tRNA genes which partially decrease the efficiency of 
translation are also more likely to affect Complex I func- 
tion because of the numerical dominance of Complex I 
transcripts. 
3.2. The most frequent mtDNA deletion eliminates more 
subunits of Complex I than any other mitochondrial en- 
zyme 
The mtDNA deletion that occurs most frequently in 
Kearns-Sayres Syndrome [17] also occurs in postmitotic 
Table 1 
Bases of the mitochondrial genome devoted to protein 
Enzyme Genes Bases Percent 
Complex I ND 1-6, ND4L 6338 56 
Complex IV COI-III 3003 27 
Complex II Cyt. b 1140 10 
ATPase ATPase 6,8 839 7 
Total 11320 
Table 2 
CUN and UUR codons in human mitochondrial genes 
Complex I Non-Complex I 
8iGene UUR CUN Percent Gene UUR CUN Percent 
NDI 6 57 l0 COl 7 55 I 1 
ND2 9 55 14 COIl 5 28 15 
ND3 10 18 36 " ATPase8 2 8 20 
ND4 9 87 9 ATPase6 5 39 11 
ND4L 1 22 4 COIII 3 31 9 
ND5 9 95 9 Total 22 161 12 
ND6 14 3 82 * * -i 
Total 58 337 15 
The usage of CUN and UUR codons in Complex I and non-Complex I 
proteins encoded on the mitochondrial genome. Single or double asterisks 
(* ,**)  signify Chi-square deviation from mean expectation of UUR 
codons in Complex I genes (15%) at the P < 0.01 level and P < 0.001 
level, respectively. ND6 (t) is the only mitochondrial protein whose RNA 
is transcribed from the heavy strand. 
cells of aged humans [3-7]. This deletion erases coding 
information for four subunits of Complex I, but only one 
subunit of Complex IV, and one subunit of ATPase. Other 
mtDNA deletions also accumulate with age [18], which are 
centred in the region between the light and heavy-strand 
origins of replication. These deletions frequently erase 
coding information for the genes ND3, ND4, ND4L, and 
ND5, all subunits of Complex I. 
3.3. The reported rise in mutant RNA ce"wvg) with age is 
more likely to affect decoding of Complex I mRNAs than 
others 
One of the more common mitochondrial diseases is 
MELAS (Myoclonic Epilepsy, Lactic Acidosis, and 
Stroke), attributable to point mutations in the tRNA LeuwvR) 
that decodes leucine codons [19,20]; the remaining 
tRNA Leu~cuN) is not associated with disease. Such 
tRNALeu(VUR)mutations could have the effect of decreasing 
translation efficiency of particular messages with high 
usage of UUR codons. The 3243 MELAS mutation rises in 
frequency with age [21,22]. One may inspect he sequence 
of the mitochondrial genome to assess which mitochon- 
drially encoded genes are most likely to be affected by 
mutations in the UUR decoding tRNA. In fact, 73% of 
such codons are found in subunits of Complex I, more than 
twice the number found (27%) in non-Complex I encoding 
genes (Table 2). 
As Table 2 shows, the ND6 gene has an extremely high 
frequency of UUR codons (82%), and might therefore be 
disproportionately affected by tRNA Leu(UUR) mutations that 
decreased the translation efficiency of messages bearing 
such codons. In fact, in vitro studies have shown that cells 
with a high fraction of a tRNA Leu(UUR) mutation are specif- 
ically defective in Complex I activity, and are specifically 
unable to correctly translate the ND6 message, a subunit of 
Complex I [23]. The inversion of UUR to CUN codon 
usage in the ND6 gene is most likely explained by the 
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unique inversion of the ND4 gene with respect to other 
protein encoding genes on the mtDNA. Because of its 
inverted orientation, the sense strand of the ND4 gene is 
the mtDNA light strand, which is deficient in cytosine. 
Low usage of cytosine in the light strand is better achieved 
by UUR codons, which contain no cytosine, than CUN 
codons, which may contain one or two cytosines. The 
evolutionary force which maintains low cytosine in the 
more often unpaired light strand is thought o be deamina- 




3.4. Drugs that induce Complex I deficiency cause ceil 
death 
If one desires to model the effect of mitochondrial DNA 
mutations on aging cells, a reasonable first step is to look 
at the effects of inhibitors of Complex I. Two specific 
inhibitors of Complex I (rotenone and MPP ÷) have the 
effect of inducing cell death. The mechanism by which cell 
death is induced by these mitochondrial inhibitors has not 
been elucidated, but one possibility is that cell death is the 
result of a rise in mitochondrial reactive oxygen species. 
To address this issue, we attempted to identify experimen- 
tal animals with excesses or deficiencies of the sole en- 
zymic scavenger of mitochondrial superoxide, MnSOD. 
3.5. Mice with deletions and duplications of the Tme locus 
have deficiencies and excesses of MnSOD 
Mice with deficiencies at the Tme (T-associated mater- 
nal effect) locus are also deficient in activity of the mito- 
chondrial superoxide dismutase, MnSOD [16]. Deficien- 
cies at the Tme locus are inherited in a mode that is unique 
in all of mouse genetics, in that deletions at Tme inherited 
from the father (i.e., the haploid sperm) result in viable 
progeny, but such deletions inherited from the mother (i.e., 
the haploid egg) are lethal [24]. This maternal effect has 
been attributed to genomic imprinting [25]. Deletions of 
the Tme locus remove the coding region for MnSOD, the 
mitochondrial superoxide dismutase [26]. Animals bearing 
heterozygous Tme deletions have 50% of normal MnSOD 
activity, and animals with heterozygous duplications of 
Tme have 150% of normal MnSOD activity [16]. Haploid 
eggs that bear a deletion of MnSOD should have zero 
MnSOD activity, and mitochondrial oxidative damage may 
explain the lethality observed in fetuses derived from these 
eggs [16]. Deficiencies of MnSOD in haploid male sperm 
are less likely to lead to fetal lethality because male sperm 
do not contribute mitochondria to the zygote. 
Fig. 1. Mice were treated with 15 mg/kg MPTP i.p. four times at 
intervals of 2 h, then sacrificed 21 days post-treatment, and brains were 
sectioned. Panel A, left side, 100% MnSOD; right side 50% MnSOD. 
Panel B, 50% MnSOD animals, left side no MPTP, right side plus MPTP. 
Massive nlargement of he lateral ventricle isobserved inMnSOD-defi- 
cient animals treated with MPTP. Holes in the striatum are the result of 
samples punched out for dopamine measurements. 
observed in littermates with 100% MnSOD and animals 
with 150% and 200% MnSOD (Fig. 1 and [27]). A dose of 
100 mg/kg  MPTP is lethal to MnSOD-deficient animals, 
but not to animals with normal or excess MnSOD [27]. 
Thus, massive MPTP toxicity occurs in animals with defi- 
ciencies but not excesses of the enzyme that metabolizes 
mitochondrial superoxide. 
4. Discussion 
4.1. Random and observed somatic mutation of the mito- 
chondrial genome is more likely to affect Complex I 
activity than other mitochondrial enzymes 
Somatic mutations of the mitochondrial genome occur 
and increase with age (reviewed in [28]). Both point 
mutations and deletion mutations have been reported. The 
statistical analysis presented here demonstrates that ran- 
dom mutations of mtDNA are much more likely to occur 
in genes encoding Complex I than any other mitochondrial 
protein. A random mtDNA mutation is about twice more 
likely to occur in a gene encoding Complex I than in a 
Complex IV gene, and eight and six fold more likely than 
mutations in ATPase or cytochrome b, respectively, (Table 
1). Because of the inversion of ND6 and the coincidence 
of ND3-5 with the region of mtDNA most frequently 
deleted in aging cells, mutations that have been demon- 
strated to increase with age may disproportionately affect 
Complex I genes. 
3.6. Mice with deficiencies in MnSOD activity are hyper- 
sensitive to the inhibitor of Complex L MPTP 
4.2. Complex I deficiency may increase the concentration 
of mitochondrial superoxide 
MnSOD-deficient mice exhibit massive brain toxicity 
when treated with MPTP, a level of toxicity that is not 
Animals with deficiencies in the sole mitochondrial 
scavenger of superoxide, MnSOD, exhibit much more cell 
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death in the brain than animals with normal or excess 
levels of this enzyme when treated with MPTP (Fig. 1 and 
[27]). In vivo, MPTP is metabolized to MPP ÷, a selective 
inhibitor of Complex I [14]. The simplest explanation of 
the inhibitability of MPTP-induced cell death by MnSOD 
is that such death is mediated through an increase in 
mitochondrial superoxide concentration. 
These data were surprising in that it has been assumed 
by many that because superoxide is short-lived and a 
relatively weak oxidant it may be a less physiologically 
significant oxin than its product hydrogen peroxide. Our 
data support he view that excess mitochondrial superoxide 
concentration has a very significant deleterious effect (cell 
death) from which animals with more hydrogen peroxide 
and less superoxide are protected. 
Complex I 
defidency MnSOp 




• OH + HO- + FeII| 
Damage~and toxicity 
CELL DEATH 
Fig. 3. An increased level of mitochondrial superoxide may lead to cell 
death by promoting hydroxyl radical formation. 
4.3. How could Complex I inhibition lead to excess uper- 
oxide ? 
There is ample in vitro support for the finding that the 
inhibitors of Complex I rotenone and MPP + induce the 
formation of mitochondrial superoxide [29-33]. Several 
authors have claimed that the site of superoxide production 
in Complex I inhibited mitochondrial is Complex I itself 
[29-33]. By contrast, Ramsay and Singer claim that super- 
oxide resulting from rotenone treatment is not produced at 
the Complex I site [34]. 
We note that whether MPP + treatment induces uperox- 
ide formation directly at Complex I or not, that partial 
inhibition of Complex I would still leave electron transport 
from Complex II unaffected (Fig. 2). Electrons channelled 
via Complex II produce about 4 times more mitochondrial 
superoxide than electrons channelled via Complex I [35]. 
Thus the partial inhibition of Complex I by MPP ÷ should 
favor the transfer of electrons by Complex II, and hence a 
higher production of superoxide anion. 
4.4. How could an increased level of superoxide cause cell 
death? 
As explained above, the combination of impairment of 
Complex I and deficiency of superoxide removal results in 
massive cell death. How could superoxide cause mitochon- 
drial toxicity? One possibility is that superoxide anion may 
promote the Fenton reaction. Superoxide can reduce Fe III 
(the state in which iron is normally found in the cell), to Fe 
II. Fe II can react with hydrogen peroxide to form the 
highly toxic hydroxyl radical (Fig. 3). Damage by this 
radical may be a signal for cell death. 
Also, Complex I deficiency causes lactic acidosis, which 
should favor the protonation of superoxide (pKa = 4.6) to 
the very reactive hydroperoxyl radical, HO2.. A drop in 
the pH of the mitochondrial matrix from 8 to 6 would 
result in 100-fold more hydroperoxyl radical. Either or 
both of these mechanisms could provide a basis for how 
superoxide can mediate toxicity. 
O nrz] 
~ ~  Q2 ,0~ MnSOI~ H202 
NADH ~ : " N ~ ~  ~ Complex ,II, IV 
,N /r...2e-. 
FAD FADH2 
Succinate ~ Fumarate 
Fig. 2. How a partial inhibition of Complex I may favor the production of 
mitochondrial superoxide. 
4.5. Hydrogen peroxide's toxicity is repressed by the mito- 
chondrial repressor of cell death BCL2 
Other support for a mitochondrial signal for pro- 
grammed cell death has recently become available. The 
repressor of programmed cell death (apoptosis) BCL2 is 
primarily a mitochondrial protein [36]. Intriguingly, apop- 
tosis induced by hydrogen peroxide can be rescued by 
overexpression of BCL2 in neuronal cells and lympho- 
cytes, from which one may infer that the signal for cell 
death is mitochondrial [37,38]. We interpret these data in 
light of the model presented in Figs. 3 and 4, i.e., that 
hydrogen peroxide might short-circuit the toxic effect of 
intramitochondrial superoxide, by providing one of the two 
reagents critical for the Fenton reaction. The high level of 
mitochondrial mutation in dopaminergic ells [11-13] 
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Cel l  death 
( 
Fig. 4. Legend. A model to explain increased apoptosis as a result of 
inhibition of mitochondrial Complex I. MAO = monoamine oxidase, 
Fe = Fe II, Mn = Mn II, BCL2 = B cell lymphoma/leukemia locus-2 
protein, BAX = B cell death acceleration protein, PCD = programmed 
cell death. 
might then be the result of a relatively high concentration 
of Fenton reagents (Fig. 4). If the model presented in Fig. 
4 is correct, one would expect he toxicity of mitochondrial 
superoxide-generating agents to be rescued by overexpres- 
sion of BCL2. 
4.6. How could mitochondrially signalled cell death medi- 
ate aging phenotypes? 
A common theme among many age-related egenera- 
tive diseases is early or inappropriate c ll death of postmi- 
totic cells. For example, there is death of dopaminergic 
neurons in normally aging people [39]. If that loss exceeds 
80% of dopaminergic neurons present at birth, Parkinson- 
ism will develop. Similarly, in normal aging there is death 
of sensorineural hair cells of the inner ear, leading to 
presbycusis. The dementia associated with Alzheimer's 
disease is the result of death of cholinergic neurons, and 
late-onset diabetes is usually the result of death of pancre- 
atic islet cells. Intriguingly, all of the same phenotypes 
mentioned above (deafness, dementia, ataxia, and diabetes) 
occur in persons with mitochondrial genetic disease; these 
phenotypes may have a common basis. 
4.7. The age-related ecline in tissue function might be the 
result of crossing an apoptotic threshold rather than a 
bioenergetic one 
It has been proposed that the accumulation of mitochon- 
drial mutation may lead to bioenergetic decline, and that 
such bioenergetic decline will affect some specific tissues 
that have a high threshold requirement for energy like 
neurons and muscle cells before other cell types like liver 
or kidney [40]. 
An alternative model is that apoptosis occurs at differ- 
ent rates in postmitotic ells with different mitochondrial 
superoxide l vels, and that tissue dysfunction i  mitochon- 
drial disease and in aging humans is the result of loss of a 
number of cells sufficient for tissue function (Fig. 5). 
Unlike the bioenergetic threshold model, under the super- 
oxide-mediated apoptosis model the bioenergetic require- 
ment of the different issues may be identical. The super- 
oxide-mediated apoptosis model predicts that cells with 
higher levels mitochondrial superoxide, or of compounds 
that induce Fenton Chemistry (i.e., Hydrogen Peroxide, Fe, 
and Mn), should undergo more mitochondrial oxidative 
damage and more cell death, consistent with the findings 
of higher mitochondrial DNA damage and mutation in 
dopaminergic neurons. 
Bioenergetic Threshold Model for Aging 
100% -
dopaminergic 
"5 r~,  
hepatocytes 
t ime 
Superoxide apoptosis model for aging 
100% - "~hepatocytes  
dopaminergic z ~ ~ % of cells 
neurons \ \ required for 
~ tissue function 
t ime 
Fig. 5. Two mitochondrial models for aging: bioenergetic threshold and 
superoxide apoptosis. 
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